The abstract is read at the publisher; the summary is JClub's.
In a multicenter prospective cohort of 374 hospitalized patients with invasive ceftriaxone-resistant Enterobacterales bacteremia, ertapenem-resistant isolates were linked to higher 30-day mortality (OR 2.24, 95% CI 1.26–3.98).
- Why it matters: IDSA guidance recommends higher-order carbapenems for ertapenem-resistant, non-carbapenemase-producing Enterobacterales, but clinical outcome evidence is limited.
- What they did: Patients received definitive imipenem or meropenem for more than 72 hours, with carbapenem susceptibility confirmed by broth microdilution and carbapenemase genes absent; inverse probability weighting and logistic regression compared 30-day mortality between ertapenem-susceptible (ETP-S) and ertapenem-resistant (ETP-R) isolates.
- The result: ETP-R infection predicted higher 30-day, 14-day, and in-hospital mortality, with the highest mortality in isolates resistant to two carbapenems; genomics showed more porin alterations and additional non-carbapenemase β-lactamase genes (e.g., blaCTX-M, blaOXA-10).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.